ITGAL

Across TCGA pan-cancer cohorts, ITGAL Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ITGAL data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in thyroid carcinoma (THCA), where higher ITGAL Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ITGAL expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

THCA, UCEC, and SARC are the cancer types where ITGAL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	OS	Median	All	0.032	0.941	<.001	48	view →
UCEC	DFS	Median	All	0.979	0.607	<.001	32	view →
SARC	OS	Median	All	0.126	0.860	<.001	12	view →
COAD	DFS	Median	II,III,IV	0.214	0.753	<.001	9	view →
LUSC	DFS	Median	All	1.000	0.653	.035	4	view →
SCLC	OS	Median	IV	0.772	0.201	.024	3	view →
SKCM	DFS	Median	II,III,IV	0.857	0.655	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ITGAL–THCA (OS)

Open the THCA breakdown →